The degree of improvement did not differ significantly between the groups. Visual acuity improved significantly at 12Â months in both groups compared with before surgery. During follow-up, 11 patients dropped out (six in the study group and five in the control group), leaving 28 eyes in 28 patients for analysis (13 in the study group and 15 in the control group). The main outcome measurements included logMAR visual acuity and central foveal thickness (CFT) before surgery and at 3, 6, 9, and 12Â months after vitrectomy. This study was designed as a prospective, randomized, multicenter study comparing 19 eyes of 19 patients who received 150 units of kallidinogenase administered a day for 52Â weeks from the day after vitrectomy (study group) with 20 eyes of 20 patients who received no kallidinogenase (control group). To evaluate the effectiveness of the combination of vitrectomy with kallidinogenase for diabetic macular edema (DME). Yoshizumi, Yuki Ohara, Zaigen Tabuchi, Hitoshi Sumino, Hitomi Maeda, Yukiko Mochizuki, Hideki Yamane, Ken Kiuchi, Yoshiaki Note that the list of references may not be complete.Effects of kallidinogenase in patients undergoing vitrectomy for diabetic macular edema.

It uses data fromĬVE version 20061101 and candidates that were active as of

Provides the associated CVE entries or candidates. This reference map lists the various references for CONFIRM and

Note that in some cases, the provider may have deleted or overwritten the portion of the web page that acknowledged the vulnerability or exposure. The URL for the confirmation is specified in the name. This source is only used when a vendor confirms an issue with its own advisory, but the vendor is not otherwise a CVE reference source.

URL to location where vendor confirms that the problem exists CVE Reference Map for Source CONFIRM Source

Miranda NG 0.96.3 instaling